PLEASE NOTE: The information provided on this page is intended for general informational purposes only
Endocrinology Diabetes & Metabolism, 7(1)
Next-generation obesity drugs are exploring combinations of GLP-1 with other entero-pancreatic hormones, such as GIP, glucagon, and amylin, to amplify weight loss and cardiometabolic benefits
Meanwhile, as this segment of the population focuses on themselves, Circana uncovered a decline in many pet segments outside of pet food. Circana also found that certain retail channels resonate with GLP-1 users, as their spending tends to shift away from mass and dollar stores and toward club stores and e-commerce retailers during their first year of active usage of the medication
,
Yes, enhanced monitoring is necessary including glucose parameters every 3 months, comprehensive metabolic panels every 36 months, periodic IGF-1 levels, and clinical surveillance for gastrointestinal symptoms, gallbladder disease, and growth hormone-related effects
